Melatonin is named as an intervention in 23 current clinical trials in our Egypt, Denmark, Australia, Netherlands, Sweden, Switzerland, Canada and Mexico registers. 17 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Tanta University (5). The most-studied condition is Insomnia.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
9 single-substance products containing Melatonin on the HPRA medicines list.
No entry for Melatonin in the EMA, FDA or German BfArM shortage lists we track.
| Condition (as registered) | Trials |
|---|---|
| Insomnia | 2 |
| Oral Melatonin | 2 |
| Chronic Low-back Pain (cLBP) | 1 |
| Uveal Melanoma | 1 |
| Uveal Melanoma, Posterior, Medium/Large Size | 1 |
| Eye Cancer, Intraocular Melanoma | 1 |
| Psychiatric Disorders | 1 |
| Bipolar Affective Disorder | 1 |
| Emergence Delirium | 1 |
| Hypoactive Delirium | 1 |
| Delirium | 1 |
| Obstructive Sleep Apnea of Adult | 1 |
| Fetal Growth Retardation | 1 |
| Stillbirth and Fetal Death | 1 |
| Pregnancy Preterm | 1 |
| Post Tonsillectomy Emergence Agitation | 1 |
| Breast Cancer | 1 |
| Oral | 1 |
| Melatonin | 1 |
| Pregabalin | 1 |
| Postoperative Pain | 1 |
| Nebulized Dexmedetomidine | 1 |
| Emergence Agitation | 1 |
| Children | 1 |
| Sleep Disturbance | 1 |
| Cardiomyopathies | 1 |
| Diabetic Peripheral Neuropathy | 1 |
| Diabetic Neuropathy | 1 |
| Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients | 1 |
| ICS | 1 |
| Ureteral Stent-Related Symptoms | 1 |
| Ureteral Calculi | 1 |
| Lower Urinary Tract Symptoms | 1 |
| Therapy | 1 |
| Treatment | 1 |
| Dental Implants | 1 |
| Immediate Implant Placement | 1 |
| Osseointegration | 1 |
| Lidocaine Infusion | 1 |
| Postoperative Delirium | 1 |
| Elderly Patients | 1 |
| Tracheal Intubation Morbidity | 1 |
| Laryngoscopy | 1 |
| Hemodynamic Response | 1 |
| Lead sponsor | Trials |
|---|---|
| Tanta University | 5 |
| Benha University | 3 |
| Ain Shams University | 2 |
| Bart Koes | 1 |
| Gustav Stalhammar | 1 |
| Lone Baandrup | 1 |
| Lars Vedel Kessing | 1 |
| Arash Afshari | 1 |
| University Hospital, Basel, Switzerland | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1 |
| Monash University | 1 |
| Woolcock Institute of Medical Research | 1 |
| Mansoura University | 1 |
| Beni-Suef University | 1 |
+ 1 more sponsors in the trial list above.
A trial with sites in more than one country appears in each of those registers.
23 current trials in our Egypt, Denmark, Australia, Netherlands, Sweden, Switzerland, Canada and Mexico registers name Melatonin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 17 of the 23 trials are recruiting: 8 with sites in Egypt, 3 with sites in Denmark, 2 with sites in Australia, 1 with sites in Sweden, 1 with sites in Switzerland, 1 with sites in Canada and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tanta University (5), Benha University (3), Ain Shams University (2) and Bart Koes (1), among 16 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 9 single-substance products containing Melatonin, for example Meladura 2 mg prolonged-release tablets (Bluefish Pharmaceuticals AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Melatonin has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Melatonin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Melatonin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Melatonin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.